Cadrenal Therapeutics

CVKD

Market cap $26.4M

PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.

Acquisition significantly enhances the Company's pipeline by adding novel assets in acute and chronic anticoagulation settings Company is strategically poised to deliver differentiated therapeutics across the spectrum of cardiovascular thrombotic risk PONTE VEDRA, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced the acquisition of the assets of eXIthera Pharmaceuticals (“eXIthera”), including its proprietary portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors.

PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal Therapeutics reports on Second Quarter 2025 financial results and provides corporate update on strategic clinical trial plans.

PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal announces clinical trial initiation plans for tecarfarin in patients with end-stage kidney disease (ESKD) who are transitioning to dialysis.

PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #cadrenaltherapeutics--Cadrenal Therapeutics highlights new research on the economic and medical burden associated with oral anticoagulation for LVAD patients.

PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CKVD--Cadrenal Therapeutics will participate at this year's BIO International Convention 2025, taking place June 16-19, 2025 in Boston.

PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #ESKD--Cadrenal announces manufacturing and supply chain milestones for its lead drug, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant.

PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #CadrenalTherapeutics--Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update.

PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #CadrenalTherapeutics--Cadrenal Therapeutics to present at inaugural Centri Capital Conference at Nasdaq on April 22, 2025.

PONTE VEDRA, Fla.--(BUSINESS WIRE)-- #anticoagulation--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company's commitment to advancing innovation and clinical development in anticoagulation therapy. Chief Operating Officer, Jeff Cole and Chief Medi.